EarliTec Diagnostics is an Atlanta-based startup whose FDA-authorized system uses AI to track eye movements while a child watches short videos and social interactions to assist autism diagnosis. The tablet-based test takes about 12 minutes and targets children aged 16 to 30 months, aiming to shorten the multi-hour traditional assessment and reduce wait times. Its technology is currently used by eight clinicians across six U.S. states. The company raised new capital to expand commercialization and to fund research intended to broaden the age range it can assess and to improve assessment and treatment options. CEO Tom Ressemann emphasized the device’s flexibility to be used in clinics, schools, or at home so it can fit into existing workflows. The fresh funding will support those commercialization and research efforts. EarliTec Dx develops objective diagnostic and therapeutic products for children with Autism Spectrum Disorder using its EarliPoint® system and Dynamic Quantification of Social-Visual Engagement (DQSVE). The EarliPoint Evaluation is an investigational device that captures moment-by-moment looking behavior at 120 Hz while a child watches videos and compares each data point to a clinically validated database. The technology was developed with researchers at Children’s Healthcare of Atlanta, Emory University School of Medicine, and Yale University, and the company has completed clinical trials with more than 1,500 children. EarliTec received FDA breakthrough designation for the EarliPoint system in April of last year. The company plans to seek FDA 510(k) clearance, commercialize the EarliPoint system, and expand its digital biomarkers built on a proprietary multimodal AI platform. A recent $19.5 million financing will fund regulatory filing, commercialization, and further development.

Total raised

$41M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2024